← All trials
NCT06048588
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 8, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Nov 15, 2024
- First posted
- Sep 21, 2023
- Last posted
- Oct 11, 2023
- Enrollment
- 128
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Inno Medicine Co., Ltd.Lead sponsor
- Beijing Inno Medicine Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.